{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T21:05:29Z","timestamp":1783890329715,"version":"3.55.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00613-1","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:02:49Z","timestamp":1783742569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook"],"prefix":"10.1007","volume":"34","author":[{"given":"Aakash","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"613_CR1","unstructured":"019732s045,020517s043lbl (n.d.)"},{"issue":"1","key":"613_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13065-018-0434-1","volume":"12","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahmad R, Alam MA, Ahmad FJ. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem Central J. 2018;12(1):65. https:\/\/doi.org\/10.1186\/s13065-018-0434-1.","journal-title":"Chem Central J"},{"issue":"5","key":"613_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/op.24.00242","volume":"21","author":"S Alaklabi","year":"2025","unstructured":"Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, et al. Real-world clinical outcomes with Sacituzumab Govitecan in metastatic triple-negative breast cancer. JCO Oncol Pract. 2025;21(5):620\u20138. https:\/\/doi.org\/10.1200\/op.24.00242.","journal-title":"JCO Oncol Pract"},{"key":"613_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122728","author":"HO Alsaab","year":"2022","unstructured":"Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, Alshehri BY, Saleh MA, et al. PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14122728.","journal-title":"Pharmaceutics"},{"key":"613_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122899","author":"AN Al-Thani","year":"2024","unstructured":"Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024. https:\/\/doi.org\/10.1016\/j.lfs.2024.122899.","journal-title":"Life Sci"},{"issue":"1","key":"613_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41120-022-00060-7","volume":"8","author":"M Alvi","year":"2022","unstructured":"Alvi M, Yaqoob A, Rehman K, Shoaib SM, Akash MSH. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022a;8(1):12. https:\/\/doi.org\/10.1186\/s41120-022-00060-7.","journal-title":"AAPS Open"},{"issue":"1","key":"613_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s11671-024-04172-9","volume":"19","author":"MA Ambele","year":"2024","unstructured":"Ambele MA, Maebele LT, Mulaudzi TV, Kungoane T, Damane BP. Advances in nano-delivery of phytochemicals for glioblastoma treatment. DiscoverNano. 2024;19(1):216. https:\/\/doi.org\/10.1186\/s11671-024-04172-9.","journal-title":"DiscoverNano"},{"issue":"1","key":"613_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0169-409x(97)00048-3","volume":"28","author":"JM Anderson","year":"1997","unstructured":"Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5\u201324. https:\/\/doi.org\/10.1016\/s0169-409x(97)00048-3.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"613_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101538","volume":"13","author":"M Argenziano","year":"2021","unstructured":"Argenziano M, Arpicco S, Brusa P, Cavalli R, Chirio D, Dosio F, et al. Developing actively targeted nanoparticles to fight cancer: Focus on Italian research. Pharmaceutics. 2021;13(10):1538. https:\/\/doi.org\/10.3390\/pharmaceutics13101538.","journal-title":"Pharmaceutics"},{"key":"613_CR10","doi-asserted-by":"publisher","unstructured":"Azimi S. Intelligent nanoparticle design: Unlocking the potential of AI for transformative drug delivery. Curr Opin Biomed Eng. 2025;36:100625. https:\/\/doi.org\/10.1016\/J.COBME.2025.100625","DOI":"10.1016\/J.COBME.2025.100625"},{"issue":"1","key":"613_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01783-z","volume":"26","author":"X Baez-Navarro","year":"2024","unstructured":"Baez-Navarro X, van den Ende NS, Nguyen AH, Sinke R, Westenend P, van Brakel JB, et al. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: are they connected? Breast Cancer Res. 2024;26(1):41. https:\/\/doi.org\/10.1186\/s13058-024-01783-z.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"613_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/17435889.2024.2440302","volume":"20","author":"A Bakhtiar","year":"2025","unstructured":"Bakhtiar A, Kuan XY, Chowdhury EH. The potential of nanoparticle-based siRNA delivery in breast cancer treatment. Nanomedicine. 2025;20(6):531\u20133. https:\/\/doi.org\/10.1080\/17435889.2024.2440302. (Taylor and Francis Ltd.).","journal-title":"Nanomedicine"},{"issue":"1","key":"613_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00741-y","volume":"11","author":"Y Bar","year":"2025","unstructured":"Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025;11(1):27. https:\/\/doi.org\/10.1038\/s41523-025-00741-y.","journal-title":"NPJ Breast Cancer"},{"issue":"16","key":"613_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/nejmoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/nejmoa2028485.","journal-title":"N Engl J Med"},{"issue":"1","key":"613_CR15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s12672-025-02910-8","volume":"16","author":"S Basu","year":"2025","unstructured":"Basu S, Sasikumar S, Sur S, Vaidya V, Kheur S, Gupta S, et al. From lab to life: technological innovations in transforming cancer metastasis detection and therapy. Discov Oncol. 2025;16(1):1517. https:\/\/doi.org\/10.1007\/s12672-025-02910-8. (Springer Science and Business Media B.V.).","journal-title":"Discov Oncol"},{"issue":"11","key":"613_CR16","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3390\/cancers16112012","volume":"16","author":"G Battogtokh","year":"2024","unstructured":"Battogtokh G, Obidiro O, Akala EO. Recent developments in combination immunotherapy with other therapies and nanoparticle-based therapy for triple-negative breast cancer (TNBC). Cancers. 2024;16(11):2012. https:\/\/doi.org\/10.3390\/cancers16112012. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Cancers"},{"issue":"5","key":"613_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","volume":"141","author":"R Bazak","year":"2015","unstructured":"Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769\u201384. https:\/\/doi.org\/10.1007\/s00432-014-1767-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"613_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS8939","volume":"6","author":"J Bhattacharyya","year":"2015","unstructured":"Bhattacharyya J, Bellucci JJ, Weitzhandler I, McDaniel JR, Spasojevic I, Li X, et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat Commun. 2015;6:7939. https:\/\/doi.org\/10.1038\/NCOMMS8939.","journal-title":"Nat Commun"},{"issue":"11","key":"613_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"613_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"613_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"issue":"18","key":"613_CR22","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1039\/d3lc00531c","volume":"23","author":"C Bouquerel","year":"2023","unstructured":"Bouquerel C, Dubrova A, Hofer I, Phan DTT, Bernheim M, Ladaigue S, et al. Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies. Lab Chip. 2023;23(18):3906\u201335. https:\/\/doi.org\/10.1039\/d3lc00531c.","journal-title":"Lab Chip"},{"key":"613_CR23","doi-asserted-by":"publisher","unstructured":"Camorani S, Tortorella S, Agnello L, et al. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. Pharmaceutics. 2022;14(10):2225. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14102225","DOI":"10.3390\/PHARMACEUTICS14102225"},{"key":"613_CR24","unstructured":"cancer 02. n.d."},{"key":"613_CR25","doi-asserted-by":"publisher","first-page":"707319","DOI":"10.3389\/fbioe.2021.707319","volume":"9","author":"D Chang","year":"2021","unstructured":"Chang D, Ma Y, Xu X, Xie J, Ju S. Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol. 2021;9:707319. https:\/\/doi.org\/10.3389\/fbioe.2021.707319. (Frontiers Media S.A.).","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"613_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1039\/d1ma00600b","volume":"3","author":"M Chatterjee","year":"2022","unstructured":"Chatterjee M, Chanda N. Formulation of PLGA nano-carriers: specialized modification for cancer therapeutic applications. Mater Adv. 2022;3(2):837\u201358. https:\/\/doi.org\/10.1039\/d1ma00600b.","journal-title":"Mater Adv"},{"issue":"4","key":"613_CR27","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/S13346-022-01273-9","volume":"13","author":"D Chaudhari","year":"2023","unstructured":"Chaudhari D, Kuche K, Yadav V, Ghadi R, Date T, Bhargavi N, et al. Exploring paclitaxel-loaded adenosine-conjugated pegylated PLGA nanoparticles for targeting triple-negative breast cancer. Drug Deliv Transl Res. 2023;13(4):1074\u201387. https:\/\/doi.org\/10.1007\/S13346-022-01273-9.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"613_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12957-w","volume":"15","author":"H Chen","year":"2025","unstructured":"Chen H, Zhang L, Liu P, Ji L, Luo C, Peng B, et al. A whole slide image-based risk score predicts prognosis and postmastectomy radiotherapy benefit in triple negative breast cancer patients. Sci Rep. 2025;15(1):31255. https:\/\/doi.org\/10.1038\/s41598-025-12957-w.","journal-title":"Sci Rep"},{"issue":"16","key":"613_CR29","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1039\/d1ra00074h","volume":"11","author":"HI Chiu","year":"2021","unstructured":"Chiu HI, Samad NA, Fang L, Lim V. Cytotoxicity of targeted PLGA nanoparticles: a systematic review. RSC Adv. 2021;11(16):9433\u201349. https:\/\/doi.org\/10.1039\/d1ra00074h.","journal-title":"RSC Adv"},{"issue":"2","key":"613_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043.","journal-title":"J Control Release"},{"issue":"1","key":"613_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/S00210-025-04408-0","volume":"399","author":"N Dasari","year":"2026","unstructured":"Dasari N, Guntuku GS, Pindiprolu SKS. Lipid-chondroitin sulfate conjugate modified PLGA nanocarriers of salinomycin for enhanced TRAIL-mediated apoptosis in triple negative breast cancer. Naunyn-Schmiedebergs Arch Pharmacol. 2026;399(1):349\u201367. https:\/\/doi.org\/10.1007\/S00210-025-04408-0.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"613_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70202","author":"GM Demirbolat","year":"2026","unstructured":"Demirbolat GM, Kucuk A, Erdogan O, Ozer S, Kozan B, Cuceli T, et al. TRAIL-PEG-Apt-PLGA nanosystem as an aptamer-targeted drug delivery system potential for triple-negative breast cancer therapy using in vivo mouse model. Mol Oncol. 2026. https:\/\/doi.org\/10.1002\/1878-0261.70202.","journal-title":"Mol Oncol"},{"issue":"15","key":"613_CR33","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"613_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers15010008","volume":"15","author":"E Di Gregorio","year":"2023","unstructured":"Di Gregorio E, Romiti C, Di Lorenzo A, Cavallo F, Ferrauto G, Conti L. RGD_PLGA nanoparticles with docetaxel: a route for improving drug efficiency and reducing toxicity in breast cancer treatment. Cancers. 2023;15(1):8. https:\/\/doi.org\/10.3390\/cancers15010008.","journal-title":"Cancers"},{"issue":"2","key":"613_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020216","volume":"16","author":"B Diedericks","year":"2024","unstructured":"Diedericks B, Kok AM, Mandiwana V, Lall N. A review of the potential of poly-(lactide-co-glycolide) nanoparticles as a delivery system for an active antimycobacterial compound, 7-methyljuglone. Pharmaceutics. 2024;16(2):216. https:\/\/doi.org\/10.3390\/pharmaceutics16020216.","journal-title":"Pharmaceutics"},{"issue":"8","key":"613_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1208\/S12249-023-02712-7","volume":"24","author":"YH Dinakar","year":"2023","unstructured":"Dinakar YH, Rajana N, Kumari NU, Jain V, Mehra NK. Recent advances of multifunctional PLGA nanocarriers in the management of triple-negative breast cancer. AAPS PharmSciTech. 2023;24(8):258. https:\/\/doi.org\/10.1208\/S12249-023-02712-7.","journal-title":"AAPS PharmSciTech"},{"key":"613_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2147\/ijn.s18905","volume":"6","author":"R Dinarvand","year":"2011","unstructured":"Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877\u201395. https:\/\/doi.org\/10.2147\/ijn.s18905.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"613_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4274\/ejbh.galenos.2025.2024-10-2","volume":"21","author":"AK Dogra","year":"2025","unstructured":"Dogra AK, Prakash A, Gupta S, Gupta M. Prognostic significance and molecular classification of triple negative breast cancer: a systematic review. Eur J Breast Health. 2025;21(2):101. https:\/\/doi.org\/10.4274\/ejbh.galenos.2025.2024-10-2. (Galenos Publishing House).","journal-title":"Eur J Breast Health"},{"key":"613_CR39","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.ctrv.2023.102672","volume":"123","author":"A Dri","year":"2024","unstructured":"Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, et al. Breaking barriers in triple negative breast cancer (TNBC)\u2013Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treatment Rev. 2024;123:102672. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102672. (W.B. Saunders Ltd.).","journal-title":"Cancer Treatment Rev"},{"issue":"30","key":"613_CR40","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1039\/d5tb00322a","volume":"13","author":"X Du","year":"2025","unstructured":"Du X, Zhang Y, Gu B, Yang Z, Xu X, Peng H, et al. Multifunctional nanodrug-enabled mild photothermal therapy for enhanced immunotherapy in triple-negative breast cancer. J Mater Chem B. 2025;13(30):9203\u201316. https:\/\/doi.org\/10.1039\/d5tb00322a.","journal-title":"J Mater Chem B"},{"key":"613_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112394","author":"RS Fernandes","year":"2022","unstructured":"Fernandes RS, Arribada RG, Silva JO, Silva-Cunha A, Townsend DM, Ferreira LAM, et al. In vitro and in vivo effect of pH-sensitive PLGA-TPGS-based hybrid nanoparticles loaded with Doxorubicin for breast cancer therapy. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14112394.","journal-title":"Pharmaceutics"},{"issue":"3","key":"613_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/medsci13030130","volume":"13","author":"AE Fitrianti","year":"2025","unstructured":"Fitrianti AE, Wardani NO, Astuti A, Anggadiredja K, Amalia L, Putri RA, et al. Cardiotoxicity in breast cancer therapy: risks, mechanisms, and prevention strategies. Med Sci (Basel, Switzerland). 2025;13(3):130. https:\/\/doi.org\/10.3390\/medsci13030130.","journal-title":"Med Sci (Basel, Switzerland)"},{"issue":"20","key":"613_CR43","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/nejmra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348. https:\/\/doi.org\/10.1056\/nejmra1001389.","journal-title":"N Engl J Med"},{"issue":"5","key":"613_CR44","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/cancers14051198","volume":"14","author":"AI Fraguas-S\u00e1nchez","year":"2022","unstructured":"Fraguas-S\u00e1nchez AI, Lozza I, Torres-Su\u00e1rez AI. Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic. Cancers. 2022;14(5):1198. https:\/\/doi.org\/10.3390\/cancers14051198. (MDPI).","journal-title":"Cancers"},{"issue":"1\u20132","key":"613_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.04.013","volume":"282","author":"S Freiberg","year":"2004","unstructured":"Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1\u20132):1\u201318. https:\/\/doi.org\/10.1016\/j.ijpharm.2004.04.013.","journal-title":"Int J Pharm"},{"issue":"4","key":"613_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.celrep.2018.03.112","volume":"23","author":"H Fujita","year":"2018","unstructured":"Fujita H, Tokunaga A, Shimizu S, Whiting AL, Aguilar-Alonso F, Takagi K, et al. Cooperative domain formation by homologous motifs in HOIL-1L and SHARPIN plays a crucial role in LUBAC stabilization. Cell Rep. 2018;23(4):1192\u2013204. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.112.","journal-title":"Cell Rep"},{"issue":"3","key":"613_CR47","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3390\/ijms15033640","volume":"15","author":"P Gentile","year":"2014","unstructured":"Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640\u201359. https:\/\/doi.org\/10.3390\/ijms15033640.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"613_CR48","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01096-9","volume":"27","author":"HSA Ghaly","year":"2025","unstructured":"Ghaly HSA, Seyedasli N, Varamini P. Enhanced nanoprecipitation method for the production of PLGA nanoparticles for oncology applications. AAPS J. 2025;27(5):113. https:\/\/doi.org\/10.1208\/s12248-025-01096-9.","journal-title":"AAPS J"},{"key":"613_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114504","volume":"249","author":"S G\u00f3mez-Pastor","year":"2025","unstructured":"G\u00f3mez-Pastor S, Maugard A, Walker HR, Elies J, B\u00f8rsum KE, Grimaldi G, et al. CD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: targeting the tumour inside out. Colloids Surf B Biointerfaces. 2025;249:114504. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.114504.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"613_CR50","unstructured":"Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends model to the clinic: current status of polymer-drug conjugates 2.1. Polymer conjugates carrying orthodox anticancer agents 2.1.1. Polymer-Dox conjugates 2.1.2. Polymer-paclitaxel conjugates 2.1.3. Polymer-camptothecin conjugates 2.1.4. Polymer-platinate conjugates 2.2. Polymer-anticancer drug conjugates designed for active. In: Frontiers in Bioscience (Vol. 13). 2008. http:\/\/www.yamanouchi.com"},{"issue":"1","key":"613_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/S12645-025-00341-2","volume":"16","author":"Z Gui","year":"2025","unstructured":"Gui Z, Zhao L, Liu S, Zhang L. Tumor vascular disruption and cGAS\u2013STING activation by gambogic amide-loaded nanomicelles for multiple synergistic treatment of triple-negative breast cancer. Cancer Nanotechnol. 2025;16(1):39. https:\/\/doi.org\/10.1186\/S12645-025-00341-2.","journal-title":"Cancer Nanotechnol"},{"key":"613_CR52","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fonc.2014.00346","volume":"4","author":"S Guo","year":"2014","unstructured":"Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol. 2014;4:346. https:\/\/doi.org\/10.3389\/fonc.2014.00346. (Frontiers Media S.A.).","journal-title":"Front Oncol"},{"issue":"4","key":"613_CR53","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2019.03.016","volume":"50","author":"TR Hammond","year":"2019","unstructured":"Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50(4):955\u201374. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.016.","journal-title":"Immunity"},{"key":"613_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fphar.2016.00185","volume":"7","author":"FY Han","year":"2016","unstructured":"Han FY, Thurecht KJ, Whittaker AK, Smith MT. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Front Pharmacol. 2016;7:185. https:\/\/doi.org\/10.3389\/fphar.2016.00185. (Frontiers Research Foundation).","journal-title":"Front Pharmacol"},{"issue":"1","key":"613_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00729-8","volume":"11","author":"C Helal","year":"2025","unstructured":"Helal C, Djerroudi L, Ramtohul T, Laas E, Vincent-Salomon A, Jin M, et al. Clinico-pathological factors predicting pathological response in early triple-negative breast cancer. npj Breast Cancer. 2025;11(1):15. https:\/\/doi.org\/10.1038\/s41523-025-00729-8.","journal-title":"npj Breast Cancer"},{"key":"613_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addr.2020.07.006","volume":"157","author":"AJ Hickey","year":"2020","unstructured":"Hickey AJ. Emerging trends in inhaled drug delivery. Adv Drug Deliv Rev. 2020;157:63\u201370. https:\/\/doi.org\/10.1016\/j.addr.2020.07.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"613_CR57","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326. https:\/\/doi.org\/10.1038\/nrc3599.","journal-title":"Nat Rev Cancer"},{"key":"613_CR58","doi-asserted-by":"publisher","unstructured":"Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, \u2026 Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128). https:\/\/doi.org\/10.1126\/scitranslmed.3003651","DOI":"10.1126\/scitranslmed.3003651"},{"issue":"1","key":"613_CR59","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1021\/ACSOMEGA.2C06359","volume":"8","author":"H Hu","year":"2022","unstructured":"Hu H, Liao Z, Xu M, Wan S, Wu Y, Zou W, et al. Fabrication, optimization, and evaluation of Paclitaxel and Curcumin coloaded PLGA nanoparticles for improved antitumor activity. ACS Omega. 2022;8(1):976\u201386. https:\/\/doi.org\/10.1021\/ACSOMEGA.2C06359.","journal-title":"ACS Omega"},{"issue":"2","key":"613_CR60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.biomaterials.2010.09.037","volume":"32","author":"AK Jain","year":"2011","unstructured":"Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2011;32(2):503\u201315. https:\/\/doi.org\/10.1016\/j.biomaterials.2010.09.037.","journal-title":"Biomaterials"},{"issue":"23","key":"613_CR61","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/s0142-9612(00)00115-0","volume":"21","author":"RA Jain","year":"2000","unstructured":"Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials. 2000;21(23):2475\u201390. https:\/\/doi.org\/10.1016\/s0142-9612(00)00115-0.","journal-title":"Biomaterials"},{"issue":"13","key":"613_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133312","volume":"20","author":"JH Jang","year":"2019","unstructured":"Jang JH, Jeong SH, Lee YB. Preparation and in vitro\/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery. Int J Mol Sci. 2019;20(13):3312. https:\/\/doi.org\/10.3390\/ijms20133312.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"613_CR63","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.3390\/cancers15174352","volume":"15","author":"J Jin","year":"2023","unstructured":"Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and prospects of patient-derived xenografts for cancer research. Cancers. 2023;15(17):4352. https:\/\/doi.org\/10.3390\/cancers15174352. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Cancers"},{"key":"613_CR64","doi-asserted-by":"publisher","unstructured":"Jumadi J, Harun WSW, Kadirgama K, et al. A Comparative Review of Polylactic Acid and Poly(Lactic-co-Glycolic Acid) Biomaterials: Optimizing Drug Delivery. BioNanoScience. 2025;16(1):19. https:\/\/doi.org\/10.1007\/S12668-025-02233-6","DOI":"10.1007\/S12668-025-02233-6"},{"issue":"3","key":"613_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jbm.a.36840","volume":"108","author":"CH Kapadia","year":"2020","unstructured":"Kapadia CH, Ioele SA, Day ES. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells. J Biomed Mater Res A. 2020;108(3):601\u201313. https:\/\/doi.org\/10.1002\/jbm.a.36840.","journal-title":"J Biomed Mater Res A"},{"issue":"8_Supplement_1","key":"613_CR66","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/1538-7445.AM2025-1860","volume":"85","author":"F Kazdal","year":"2025","unstructured":"Kazdal F, Kahraman N, Ozpolat B. Abstract 1860: development of novel AXL inhibitor-loaded PLGA nanoparticles for targeted therapy in triple negative breast cancer. Cancer Res. 2025;85(8_Supplement_1):1860\u20131860. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-1860.","journal-title":"Cancer Res"},{"issue":"1","key":"613_CR67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","volume":"24","author":"P Kesharwani","year":"2025","unstructured":"Kesharwani P, Kumar V, Goh KW, Gupta G, Alsayari A, Wahab S, et al. PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy. Mol Cancer. 2025;24(1):205. https:\/\/doi.org\/10.1186\/s12943-025-02410-x. (BioMed Central Ltd.).","journal-title":"Mol Cancer"},{"issue":"1","key":"613_CR68","doi-asserted-by":"publisher","DOI":"10.4155\/fdd-2019-0005","volume":"1","author":"V Khanna","year":"2019","unstructured":"Khanna V, Kalscheuer S, Kirtane A, Zhang W, Panyam J. Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future Drug Discov. 2019;1(1):FDD8. https:\/\/doi.org\/10.4155\/fdd-2019-0005.","journal-title":"Future Drug Discov"},{"issue":"4","key":"613_CR69","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13346-012-0124-9","volume":"3","author":"R Kumar","year":"2013","unstructured":"Kumar R, Kulkarni A, Nabulsi J, Nagesha DK, Cormack R, Makrigiorgos MG, et al. Facile synthesis of PEGylated PLGA nanoparticles encapsulating doxorubicin and its in vitro evaluation as potent drug delivery vehicle. Drug Deliv Transl Res. 2013;3(4):299\u2013308. https:\/\/doi.org\/10.1007\/s13346-012-0124-9.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"613_CR70","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/S00210-025-04460-W","volume":"399","author":"N Laxane","year":"2026","unstructured":"Laxane N, Yadav KS. Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):797\u2013814. https:\/\/doi.org\/10.1007\/S00210-025-04460-W.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"613_CR71","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367. https:\/\/doi.org\/10.1172\/JCI45014.","journal-title":"J Clin Invest"},{"key":"613_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.MATDES.2025.114271","volume":"256","author":"M Li","year":"2025","unstructured":"Li M, Wan X, Shan B, He Y, Chen C, Shen M. A pH and GSH dual responsive nanoparticle co-deliver Adriamycin and Olaparib enhanced the therapeutic efficacy on triple negative breast cancer. Mater Des. 2025;256:114271. https:\/\/doi.org\/10.1016\/J.MATDES.2025.114271.","journal-title":"Mater Des"},{"issue":"1","key":"613_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0. (BioMed Central Ltd).","journal-title":"J Hematol Oncol"},{"key":"613_CR74","doi-asserted-by":"crossref","unstructured":"Lin ML, Zhan Y, Proietto AI, Prato S, Wu L, Heath WR, Villadangos JA, Lew AM (2008) Selective suicide of cross-presenting CD8 dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. www .pnas.orgcgi10. 1073pnas.0712394105.","DOI":"10.1073\/pnas.0712394105"},{"key":"613_CR75","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.2147\/IJN.S32830","volume":"7","author":"CW Liu","year":"2012","unstructured":"Liu CW, Lin WJ. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. Int J Nanomedicine. 2012;7:4749\u201367. https:\/\/doi.org\/10.2147\/IJN.S32830.","journal-title":"Int J Nanomedicine"},{"issue":"19","key":"613_CR76","doi-asserted-by":"publisher","first-page":"10712","DOI":"10.3390\/ijms251910712","volume":"25","author":"M Llaguno-Munive","year":"2024","unstructured":"Llaguno-Munive M, Vazquez-Lopez MI, Garcia-Lopez P. Solid lipid nanoparticles, an alternative for the treatment of triple-negative breast cancer. Int J Mol Sci. 2024;25(19):10712. https:\/\/doi.org\/10.3390\/ijms251910712. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Int J Mol Sci"},{"issue":"5","key":"613_CR77","doi-asserted-by":"publisher","first-page":"759","DOI":"10.7150\/jca.82410","volume":"14","author":"P Ma","year":"2023","unstructured":"Ma P, Huang J, Liu J, Zhu Y, Chen J, Chen J, et al. Nanoformulation of Paclitaxel: exploring the cyclodextrin \/ PLGA nano delivery carrier to slow down Paclitaxel release, enhance accumulation in vivo. J Cancer. 2023;14(5):759\u201369. https:\/\/doi.org\/10.7150\/jca.82410.","journal-title":"J Cancer"},{"issue":"17","key":"613_CR78","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/cancers14174280","volume":"14","author":"R Mahmoud","year":"2022","unstructured":"Mahmoud R, Ord\u00f3\u00f1ez-Mor\u00e1n P, Allegrucci C. Challenges for triple negative breast cancer treatment: defeating heterogeneity and cancer stemness. Cancers. 2022;14(17):4280. https:\/\/doi.org\/10.3390\/cancers14174280. (MDPI).","journal-title":"Cancers"},{"issue":"3","key":"613_CR79","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377\u201397. https:\/\/doi.org\/10.3390\/polym3031377.","journal-title":"Polymers"},{"issue":"8","key":"613_CR80","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jsps.2021.07.001","volume":"29","author":"N Maliyakkal","year":"2021","unstructured":"Maliyakkal N, Appadath Beeran A, Udupa N. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells. Saudi Pharm J. 2021;29(8):857\u201373. https:\/\/doi.org\/10.1016\/j.jsps.2021.07.001.","journal-title":"Saudi Pharm J"},{"issue":"4","key":"613_CR81","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704\u201315. https:\/\/doi.org\/10.1016\/j.cell.2008.03.027.","journal-title":"Cell"},{"issue":"18","key":"613_CR82","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.3390\/ijms241813726","volume":"24","author":"C Mark","year":"2023","unstructured":"Mark C, Lee JS, Cui X, Yuan Y. Antibody\u2013drug conjugates in breast cancer: current status and future directions. Int J Mol Sci. 2023;24(18):13726. https:\/\/doi.org\/10.3390\/ijms241813726. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Int J Mol Sci"},{"key":"613_CR83","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","volume":"159","author":"M Mir","year":"2017","unstructured":"Mir M, Ahmed N, Rehman A. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces. 2017;159:217\u201331. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.07.038. (Elsevier B.V.).","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"2","key":"613_CR84","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","volume":"15","author":"FST Mirakabad","year":"2014","unstructured":"Mirakabad FST, Nejati-Koshki K, Akbarzadeh A, Yamchi MR, Milani M, Zarghami N, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517\u201335. https:\/\/doi.org\/10.7314\/APJCP.2014.15.2.517. (Asian Pacific Organization for Cancer Prevention.).","journal-title":"Asian Pac J Cancer Prev"},{"key":"613_CR85","doi-asserted-by":"crossref","unstructured":"Monteiro MR, Nunes NCC, da Silva Junior AA, de Souza F\u00eade AB, de Bretas GO, de Souza CP, Mano M, da Silva JL. Antibody-drug conjugates in breast cancer: a comprehensive review of how to selectively deliver payloads. In: Breast Cancer: Targets and Therapy (Vol. 16). Dove Medical Press Ltd.; 2024. p. 51\u201370.","DOI":"10.2147\/BCTT.S448191"},{"issue":"11","key":"613_CR86","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1023\/B:PHAM.0000003387.15428.42","volume":"20","author":"L Mu","year":"2003","unstructured":"Mu L, Feng SS. PLGA\/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res. 2003;20(11):1864\u201372.","journal-title":"Pharm Res"},{"key":"613_CR87","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/J.PROCBIO.2024.04.007","volume":"142","author":"A Nadaf","year":"2024","unstructured":"Nadaf A, Hasan N, Ahmad S, Gupta A, Jain D, Imtiyaz K, et al. Leucocyte membrane camouflaged poly-lactic-co-glycolic acid (PLGA) nanoparticles containing cannabidiol and paclitaxel against breast cancer therapy. Process Biochem. 2024;142:88\u2013103. https:\/\/doi.org\/10.1016\/J.PROCBIO.2024.04.007.","journal-title":"Process Biochem"},{"issue":"10","key":"613_CR88","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","volume":"27","author":"Y Nakamura","year":"2016","unstructured":"Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjugate Chem. 2016;27(10):2225\u201338. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00437.","journal-title":"Bioconjugate Chem"},{"issue":"4\u20136","key":"613_CR89","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/20468954.2025.2470103","volume":"13","author":"V Nath","year":"2024","unstructured":"Nath V, Singh M, Jana BK, Sarkar T, Gogoi NR, Mazumder B. PLGA and cancer: a comprehensive patent-based review on the present state of art. Pharm Pat Anal. 2024;13(4\u20136):201\u201315. https:\/\/doi.org\/10.1080\/20468954.2025.2470103.","journal-title":"Pharm Pat Anal"},{"issue":"13","key":"613_CR90","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2217\/nnm-2016-0022","volume":"11","author":"SM Navarro","year":"2016","unstructured":"Navarro SM, Morgan TW, Astete CE, Stout RW, Coulon D, Mottram P, et al. Biodistribution and toxicity of orally administered poly (lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days. Nanomedicine. 2016;11(13):1653\u201369. https:\/\/doi.org\/10.2217\/nnm-2016-0022.","journal-title":"Nanomedicine"},{"issue":"9","key":"613_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957. https:\/\/doi.org\/10.3390\/cells8090957.","journal-title":"Cells"},{"key":"613_CR92","doi-asserted-by":"publisher","unstructured":"Nevala WK, Geng L, Xie H, et al. PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model. Int J Mol Sci. 2025;26:3295. https:\/\/doi.org\/10.3390\/IJMS26073295\/S1","DOI":"10.3390\/IJMS26073295\/S1"},{"key":"613_CR93","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Hsu FD, Jensen K (2004) Basal-like subtype of invasive breast carcinoma immunohistochemical and clinical characterization of the e-mail alerts. In: Clin Cancer Res Downloaded from Research (Vol. 10). http:\/\/clincancerres.aacrjournals.org\/content\/10\/16\/5367http:\/\/clincancerres.aacrjournals.org\/content\/10\/16\/5367.full.html#ref-list-1http:\/\/clincancerres.aacrjournals.org\/content\/10\/16\/5367.full.html#related-urls","DOI":"10.1158\/1078-0432.CCR-04-0220"},{"issue":"1","key":"613_CR94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43088-023-00458-6","volume":"12","author":"CI Nkanga","year":"2023","unstructured":"Nkanga CI. Nanotoxicological profiles of clinically approved nanoplatforms. Beni-Suef Univ J Basic Appl Sci. 2023;12(1):115. https:\/\/doi.org\/10.1186\/s43088-023-00458-6. (Springer Science and Business Media Deutschland GmbH).","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"issue":"7","key":"613_CR95","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796. https:\/\/doi.org\/10.3390\/pharmaceutics15071796. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Pharmaceutics"},{"key":"613_CR96","doi-asserted-by":"publisher","unstructured":"Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, Yan M, Tong Z, Liu YP, Wainberg ZA, Wang Y, Geng C, Ulahannan SV, Yu G, Sharma MR, Wang X, Wang JS, Spira A, Zhao W, \u2026 Yin Y. Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025;18(1). https:\/\/doi.org\/10.1186\/s13045-025-01705-2","DOI":"10.1186\/s13045-025-01705-2"},{"issue":"7","key":"613_CR97","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.3390\/curroncol29070377","volume":"29","author":"M Pauls","year":"2022","unstructured":"Pauls M, Chia S, LeVasseur N. Current and new novel combination treatments for metastatic triple-negative breast cancer. Curr Oncol. 2022;29(7):4748\u201367. https:\/\/doi.org\/10.3390\/curroncol29070377. (MDPI).","journal-title":"Curr Oncol"},{"key":"613_CR98","unstructured":"Pecchielan L. A side by side comparison of PLGA and SLN particles for the delivery of diethyldithiocarbamate-copper complex in the treatment of breast cancer. 2025. https:\/\/thesis.unipd.it\/handle\/20.500.12608\/34985"},{"key":"613_CR99","doi-asserted-by":"crossref","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. 2007. www.nature.com\/naturenanotechnology","DOI":"10.1038\/nnano.2007.387"},{"issue":"1","key":"613_CR100","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/pharmaceutics15010246","volume":"15","author":"R Pradhan","year":"2023","unstructured":"Pradhan R, Dey A, Taliyan R, Puri A, Kharavtekar S, Dubey SK. Recent advances in targeted nanocarriers for the management of triple negative breast cancer. Pharmaceutics. 2023;15(1):246. https:\/\/doi.org\/10.3390\/pharmaceutics15010246. (MDPI).","journal-title":"Pharmaceutics"},{"key":"613_CR101","doi-asserted-by":"publisher","unstructured":"Praisthy Lj C, Kushwah R, Dubey S, Kumar V, Jain S. Pharmacotherapeutic potential of daidzein: insights into mechanisms and clinical relevance. Inflammopharmacology. 2025;33:5145\u20135171. https:\/\/doi.org\/10.1007\/s10787-025-01891-y","DOI":"10.1007\/s10787-025-01891-y"},{"issue":"1","key":"613_CR102","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/s12951-025-03758-4","volume":"23","author":"C Qiu","year":"2025","unstructured":"Qiu C, Guo P, Wang C, Tu Q, Zhong LY, Fu Y, et al. Synergistic gambogic acid\/Ga3+ remodels the immunosuppressive tumor microenvironment to enhance triple-negative breast cancer therapy. J Nanobiotechnology. 2025;23(1):710. https:\/\/doi.org\/10.1186\/s12951-025-03758-4.","journal-title":"J Nanobiotechnology"},{"key":"613_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOADV.2025.214694","volume":"182","author":"C Qiu","year":"2026","unstructured":"Qiu C, Zhou X, Tu Q, Zhong LY, Fu Y, Liu Y, et al. Rosmarinic acid\/Se4+ self-assembled nanoparticles for combinational therapy of triple-negative breast cancer. Biomater Adv. 2026;182:214694. https:\/\/doi.org\/10.1016\/J.BIOADV.2025.214694.","journal-title":"Biomater Adv"},{"key":"613_CR104","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/IJN.S121881","volume":"12","author":"P Rafiei","year":"2017","unstructured":"Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017;12:935\u201347. https:\/\/doi.org\/10.2147\/IJN.S121881.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"613_CR105","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF00255282","volume":"16","author":"A Rahman","year":"1986","unstructured":"Rahman A, Ganjei A, Neefe JR. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother Pharmacol. 1986;16(1):28\u201334. https:\/\/doi.org\/10.1007\/BF00255282.","journal-title":"Cancer Chemother Pharmacol"},{"key":"613_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107180","volume":"111","author":"A Raj","year":"2025","unstructured":"Raj A, Paul A, Hariharapura RC, Aranjani JM, Soman S, Mutalik S, et al. Optimizing MYCi975 delivery using PLGA nanoparticles for triple negative breast cancer therapy: characterization and in vitro evaluation. J Drug Deliv Sci Technol. 2025;111:107180. https:\/\/doi.org\/10.1016\/j.jddst.2025.107180.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"613_CR107","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s11671-025-04308-5","volume":"20","author":"NR Ramayanam","year":"2025","unstructured":"Ramayanam NR, Bukke SP, Moka MK, Dehingia H, Bordoloi A, Debbarma R, et al. Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discover Nano. 2025;20(1):111. https:\/\/doi.org\/10.1186\/s11671-025-04308-5. (Springer).","journal-title":"Discover Nano."},{"key":"613_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3155-10-38","volume":"10","author":"AP Ranjan","year":"2012","unstructured":"Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol. 2012;10:38. https:\/\/doi.org\/10.1186\/1477-3155-10-38.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"613_CR109","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5306\/wjco.v14.i9.335","volume":"14","author":"Z-Z Rao","year":"2023","unstructured":"Rao Z-Z, Tang Z-W, Wen J. Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor. World J Clin Oncol. 2023;14(9):335\u201342. https:\/\/doi.org\/10.5306\/wjco.v14.i9.335.","journal-title":"World J Clin Oncol"},{"key":"613_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01260","volume":"9","author":"S Rezvantalab","year":"2018","unstructured":"Rezvantalab S, Drude NI, Moraveji MK, G\u00fcvener N, Koons EK, Shi Y et al (2018) PLGA-based nanoparticles in cancer treatment. Front Pharmacol 9:1260. https:\/\/doi.org\/10.3389\/fphar.2018.01260","journal-title":"Front Pharmacol"},{"issue":"6","key":"613_CR111","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/nejmoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/nejmoa1706450.","journal-title":"N Engl J Med"},{"issue":"6","key":"613_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061087","volume":"16","author":"M Rosi\u0144ska","year":"2024","unstructured":"Rosi\u0144ska M, Dubia\u0144ski R, Konieczna A, Poleszczuk J, Pawlik H, Nowecki ZI, et al. Retrospective observational study to determine the epidemiology and treatment patterns of patients with triple-negative breast cancer. Cancers Basel. 2024;16(6):1087. https:\/\/doi.org\/10.3390\/cancers16061087.","journal-title":"Cancers Basel"},{"key":"613_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2025.1710176","volume":"16","author":"C Sandoval-V\u00e1squez","year":"2026","unstructured":"Sandoval-V\u00e1squez C, C\u00e1rcamo I, Lagos P, Mu\u00f1oz A, Zavala F, Colil V, et al. Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: A systematic review. Front Pharmacol. 2026;16:1710176. https:\/\/doi.org\/10.3389\/FPHAR.2025.1710176.","journal-title":"Front Pharmacol"},{"issue":"1","key":"613_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27625-0","volume":"13","author":"J Sforzi","year":"2023","unstructured":"Sforzi J, Lanfranco A, Stefania R, Alberti D, Bitonto V, Parisotto S, et al. A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment. Sci Rep. 2023;13(1):620. https:\/\/doi.org\/10.1038\/s41598-023-27625-0.","journal-title":"Sci Rep"},{"issue":"1","key":"613_CR115","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000504345","volume":"117","author":"G Shafer","year":"2020","unstructured":"Shafer G, Arunachalam A, Lohmann P. Newborn with perinatal naphthalene toxicity after maternal ingestion of mothballs during pregnancy. Neonatology. 2020;117(1):127\u201330. https:\/\/doi.org\/10.1159\/000504345.","journal-title":"Neonatology"},{"key":"613_CR116","doi-asserted-by":"publisher","DOI":"10.37349\/ebmx.2025.101342","volume":"2","author":"K Shanahan","year":"2025","unstructured":"Shanahan K, Coen D, Nafo W. Polymer-based nanoparticles for cancer theranostics: advances, challenges, and future perspectives. Explor BioMat-X. 2025;2:101342. https:\/\/doi.org\/10.37349\/ebmx.2025.101342.","journal-title":"Explor BioMat-X"},{"key":"613_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00381","author":"X Shen","year":"2020","unstructured":"Shen X, Li T, Xie X, Feng Y, Chen Z, Yang H, et al. PLGA-based drug delivery systems for remotely triggered cancer therapeutic and diagnostic applications. Front Bioeng Biotechnol. 2020. https:\/\/doi.org\/10.3389\/fbioe.2020.00381.","journal-title":"Front Bioeng Biotechnol"},{"key":"613_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPX.2025.100440","author":"J Siepmann","year":"2025","unstructured":"Siepmann J, Siepmann F. Release mechanisms of PLGA-based drug delivery systems: A review. Int J Pharm X. 2025. https:\/\/doi.org\/10.1016\/J.IJPX.2025.100440.","journal-title":"Int J Pharm X"},{"issue":"8","key":"613_CR119","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3109\/10717544.2013.867382","volume":"21","author":"G Singh","year":"2014","unstructured":"Singh G, Pai RS. Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Drug Deliv. 2014;21(8):627\u201335. https:\/\/doi.org\/10.3109\/10717544.2013.867382.","journal-title":"Drug Deliv"},{"issue":"3","key":"613_CR120","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(03)00194-9","volume":"90","author":"VR Sinha","year":"2003","unstructured":"Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90(3):261\u201380. https:\/\/doi.org\/10.1016\/S0168-3659(03)00194-9.","journal-title":"J Control Release"},{"issue":"3","key":"613_CR121","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/jpm13030389","volume":"13","author":"MA Subhan","year":"2023","unstructured":"Subhan MA, Parveen F, Filipczak N, Yalamarty SSK, Torchilin VP. Approaches to improve EPR-based drug delivery for cancer therapy and diagnosis. J Person Med. 2023;13(3):389. https:\/\/doi.org\/10.3390\/jpm13030389. (MDPI).","journal-title":"J Person Med"},{"issue":"18","key":"613_CR122","doi-asserted-by":"publisher","first-page":"e38165","DOI":"10.1016\/j.heliyon.2024.e38165","volume":"10","author":"R Sun","year":"2024","unstructured":"Sun R, Chen Y, Pei Y, Wang W, Zhu Z, Zheng Z, et al. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. Heliyon. 2024;10(18):e38165 (Elsevier Ltd.).","journal-title":"Heliyon."},{"issue":"1","key":"613_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90792-5","volume":"11","author":"S Swetledge","year":"2021","unstructured":"Swetledge S, Carter R, Stout R, Astete CE, Jung JP, Sabliov CM. Stability and ocular biodistribution of topically administered PLGA nanoparticles. Sci Rep. 2021;11(1):12270. https:\/\/doi.org\/10.1038\/s41598-021-90792-5.","journal-title":"Sci Rep"},{"key":"613_CR124","unstructured":"Tabe 1. ELIGARD\u00ae Delivery System Composition and Constituted Product Formulation. n.d."},{"key":"613_CR125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.08.003","volume":"78","author":"SS Tang","year":"2014","unstructured":"Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of \u03b2-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014;78:3\u201313. https:\/\/doi.org\/10.1016\/j.addr.2014.08.003.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"613_CR126","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/j.clbc.2017.07.013","volume":"18","author":"KK Thakur","year":"2018","unstructured":"Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018;18(3):e393\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2017.07.013.","journal-title":"Clin Breast Cancer"},{"issue":"31","key":"613_CR127","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","volume":"20","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lync F, et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20(31):2343\u201355. https:\/\/doi.org\/10.1080\/14796694.2024.2357534.","journal-title":"Future Oncol"},{"issue":"3","key":"613_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","volume":"24","author":"NS van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CH. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: A systematic review. Int J Mol Sci. 2023;24(3):2969. https:\/\/doi.org\/10.3390\/ijms24032969.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"613_CR129","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1021\/MP800030K","volume":"5","author":"LE van Vlerken","year":"2008","unstructured":"van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm. 2008;5(4):516\u201326. https:\/\/doi.org\/10.1021\/MP800030K.","journal-title":"Mol Pharm"},{"issue":"11","key":"613_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206109","volume":"13","author":"V Venugopal","year":"2018","unstructured":"Venugopal V, Krishnan S, Palanimuthu VR, Sankarankutty S, Kalaimani JK, Karupiah S, et al. Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities. PLoS One. 2018;13(11):e0206109. https:\/\/doi.org\/10.1371\/journal.pone.0206109.","journal-title":"PLoS One"},{"issue":"19","key":"613_CR131","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.64252\/40FAB002","volume":"11","author":"A Verma","year":"2025","unstructured":"Verma A, Kumar M, Sri Manepalli H, Tiwari P, Dev S, Rajput RT, et al. Formulation and characterization of PLGA nanoparticles loaded with doxorubicin for breast cancer. Int J Environ Sci. 2025;11(19):1046\u201352. https:\/\/doi.org\/10.64252\/40FAB002.","journal-title":"Int J Environ Sci"},{"key":"613_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-212","volume":"8","author":"L Vicari","year":"2008","unstructured":"Vicari L, Musumeci T, Giannone I, Adamo L, Conticello C, De Maria R, et al. Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. BMC Cancer. 2008;8:212. https:\/\/doi.org\/10.1186\/1471-2407-8-212.","journal-title":"BMC Cancer"},{"issue":"7","key":"613_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/polym16070865","volume":"16","author":"L Wang","year":"2024","unstructured":"Wang L, Wang P, Liu Y, Mahayyudin MM, Li R, Zhang W, et al. The effect of different factors on poly (lactic-co-glycolic acid) nanoparticle properties and drug release behaviors when co-loaded with hydrophilic and hydrophobic drugs. Polymers. 2024;16(7):865. https:\/\/doi.org\/10.3390\/polym16070865.","journal-title":"Polymers"},{"issue":"1","key":"613_CR134","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1080\/10717544.2017.1406558","volume":"24","author":"S Wang","year":"2017","unstructured":"Wang S, Shao M, Zhong Z, Wang A, Cao J, Lu Y, et al. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv. 2017;24(1):1791\u2013800. https:\/\/doi.org\/10.1080\/10717544.2017.1406558.","journal-title":"Drug Deliv"},{"issue":"2","key":"613_CR135","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.nano.2015.09.014","volume":"12","author":"S Wang","year":"2016","unstructured":"Wang S, Zhang J, Wang Y, Chen M. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine. 2016;12(2):411\u201320. https:\/\/doi.org\/10.1016\/j.nano.2015.09.014.","journal-title":"Nanomedicine"},{"key":"613_CR136","unstructured":"Wellings SR, Jensen HM. On the Origin and Progression of Ductal Carcinoma in the Human Breast 1,2. n.d. Retrieved http:\/\/jnci.oxfordjournals.org\/"},{"issue":"1","key":"613_CR137","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bmjspcare-2014-000689","volume":"7","author":"B Wright","year":"2017","unstructured":"Wright B, Forbes K. Haematologists\u2019 perceptions of palliative care and specialist palliative care referral: A qualitative study. BMJ Support Palliat Care. 2017;7(1):39\u201345. https:\/\/doi.org\/10.1136\/bmjspcare-2014-000689.","journal-title":"BMJ Support Palliat Care"},{"issue":"8","key":"613_CR138","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The enhanced permeability and retention (Epr) effect: The significance of the concept and methods to enhance its application. J Person Med. 2021;11(8):771. https:\/\/doi.org\/10.3390\/jpm11080771. (MDPI).","journal-title":"J Person Med"},{"issue":"3","key":"613_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.70009","volume":"5","author":"F Xia","year":"2025","unstructured":"Xia F, Lu Y, Gong Z, Tu Q, Liang S, Wang C, et al. Cancer immunotherapy based on the bidirectional reprogramming of the tumor microenvironment by a \u201cbrakes off\/ step on the accelerator\u201d core-shell manganese phosphate\/siPD-L1 modulator. Exploration. 2025;5(3):270009. https:\/\/doi.org\/10.1002\/EXP.70009.","journal-title":"Exploration"},{"issue":"17","key":"613_CR140","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/jf202135j","volume":"59","author":"X Xie","year":"2011","unstructured":"Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem. 2011;59(17):9280\u20139. https:\/\/doi.org\/10.1021\/jf202135j.","journal-title":"J Agric Food Chem"},{"issue":"7","key":"613_CR141","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/pharmaceutics14071326","volume":"14","author":"N Yadav","year":"2024","unstructured":"Yadav N, Tripathi AK, Parveen A, Parveen S, Banerjee M. PLGA-quercetin nano-formulation inhibits cancer progression via mitochondrial dependent caspase-3, 7 and independent FoxO1 activation with concomitant PI3K\/AKT suppression. Pharmaceutics. 2024;14(7):1326. https:\/\/doi.org\/10.3390\/pharmaceutics14071326. (In <Emphasis Type=&quot;Italic&quot;>Pharmaceutics<\/Emphasis> (Vol. 16, Number 1). Multidisciplinary Digital Publishing Institute (MDPI). 10.3390\/pharmaceutics16010124).","journal-title":"Pharmaceutics"},{"issue":"2","key":"613_CR142","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/pharmaceutics16020248","volume":"16","author":"S Yan","year":"2024","unstructured":"Yan S, Na J, Liu X, Wu P. Different targeting ligands-mediated drug delivery systems for tumor therapy. Pharmaceutics. 2024;16(2):248. https:\/\/doi.org\/10.3390\/pharmaceutics16020248. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Pharmaceutics"},{"issue":"16","key":"613_CR143","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1021\/acsnano.5c00700","volume":"19","author":"J Yang","year":"2025","unstructured":"Yang J, des Rieux A, Malfanti A. Stimuli-responsive nanomedicines for the treatment of non-cancer related inflammatory diseases. ACS Nano. 2025;19(16):15189\u2013219. https:\/\/doi.org\/10.1021\/acsnano.5c00700. (American Chemical Society).","journal-title":"ACS Nano"},{"issue":"18","key":"613_CR144","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.3390\/polym16182606","volume":"16","author":"J Yang","year":"2024","unstructured":"Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, et al. Recent applications of PLGA in drug delivery systems. Polymers. 2024;16(18):2606. https:\/\/doi.org\/10.3390\/polym16182606. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"Polymers"},{"issue":"3","key":"613_CR145","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u201324. https:\/\/doi.org\/10.5306\/wjco.v5.i3.412. (Baishideng Publishing Group Co., Limited).","journal-title":"World J Clin Oncol"},{"key":"613_CR146","doi-asserted-by":"publisher","unstructured":"Xu J, Zhang M, Du W, et al. Chitosan-based high-strength supramolecular hydrogels for 3D bioprinting. Int J Biol Macromol. 2022;219:545\u2013557. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2022.07.206","DOI":"10.1016\/J.IJBIOMAC.2022.07.206"},{"issue":"7","key":"613_CR147","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3109\/09687688.2010.521200","volume":"27","author":"B Yu","year":"2010","unstructured":"Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286\u201398. https:\/\/doi.org\/10.3109\/09687688.2010.521200.","journal-title":"Mol Membr Biol"},{"key":"613_CR148","doi-asserted-by":"publisher","first-page":"990505","DOI":"10.3389\/fphar.2022.990505","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, Liu L, Wang J, Zhang H, Zhang Z, Xing G, et al. Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol. 2022;13:990505. https:\/\/doi.org\/10.3389\/fphar.2022.990505. (Frontiers Media S.A.).","journal-title":"Front Pharmacol"},{"issue":"1","key":"613_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01594-9","volume":"9","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ren Z, L\u00fc J, Mo X, Lin J, Li Y, et al. Nanoparticles carrying paclitaxel and anti-miR-221 for breast cancer therapy triggered by ultrasound. Cell Death Discov. 2023;9(1):298. https:\/\/doi.org\/10.1038\/s41420-023-01594-9.","journal-title":"Cell Death Discov"},{"issue":"1","key":"613_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31485-1","volume":"16","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Liu T, Qiao F, Li W, Hou C. Hyaluronic acid\u2013chitosan conjugated PLGA nanoparticles for dual chemo-photothermal therapy of triple-negative breast cancer. Sci Rep. 2025;16(1):1910. https:\/\/doi.org\/10.1038\/s41598-025-31485-1.","journal-title":"Sci Rep"},{"key":"613_CR151","doi-asserted-by":"publisher","first-page":"1122322","DOI":"10.3389\/fonc.2023.1122322","volume":"13","author":"W Zhang","year":"2023","unstructured":"Zhang W, Zheng X. Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy. Front Oncol. 2023;13:1122322. https:\/\/doi.org\/10.3389\/fonc.2023.1122322. (Frontiers Media S.A.).","journal-title":"Front Oncol"},{"issue":"6","key":"613_CR152","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1039\/c7ra12683b","volume":"8","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Wang X, Li B, Hou Y, Cai Z, Yang J, et al. Paclitaxel-loaded PLGA microspheres with a novel morphology to facilitate drug delivery and antitumor efficiency. RSC Adv. 2018;8(6):3274\u201385. https:\/\/doi.org\/10.1039\/c7ra12683b.","journal-title":"RSC Adv"},{"key":"613_CR153","doi-asserted-by":"publisher","unstructured":"Zhao J, Mi Y, Liu Y, Feng SS. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials. 2012;33:1948\u20131958. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2011.11.051","DOI":"10.1016\/J.BIOMATERIALS.2011.11.051"},{"issue":"5","key":"613_CR154","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1021\/acs.molpharmaceut.9b01188","volume":"17","author":"J Zhou","year":"2020","unstructured":"Zhou J, Walker J, Ackermann R, Olsen K, Hong JKY, Wang Y, et al. Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide. Mol Pharm. 2020;17(5):1502\u201315. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01188.","journal-title":"Mol Pharm"},{"issue":"1","key":"613_CR155","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24(1):156 (BioMed Central Ltd.).","journal-title":"Mol Cancer"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00613-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T21:02:44Z","timestamp":1783890164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00613-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":155,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00613-1","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"44"}}